
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Aerska
Deal Size : $21.0 million
Deal Type : Financing
Aerska Launches with $21 Million in Financing to Develop RNAi Medicines for Brain Diseases
Details : The company is developing systemically administered RNA interference (RNAi) medicines designed to silence genes that drive brain diseases.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
October 01, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Aerska
Deal Size : $21.0 million
Deal Type : Financing
